

Barcelona, June 25<sup>th</sup> 2019

## **SIGNIFICANT EVENT**

### **Conference call with analysts and institutional investors: Presentation of License Agreement of lebrikizumab for Atopic Dermatitis in Europe**

In accordance with article 227 of the Consolidated Text of the Spanish Securities Markets Law approved by the Royal Legislative Decree 4/2015 from 23 October, Almirall, S.A. ("Almirall") hereby notifies the Spanish National Securities Market Commission of the following:

We will webcast a conference call with analysts and institutional investors to introduce and explain the Lebrikizumab option today 25<sup>th</sup> June at 17.30 CET.

The event will be live streamed at [www.almirall.com](http://www.almirall.com) and the complete recording will be available today on the same webpage.

Yours sincerely,

Pablo Divasson del Fraile  
Investor Relations & Corporate Comms. Department  
[investors@almirall.com](mailto:investors@almirall.com)